In addition to detecting missed lung nodules on X-rays, the AI-powered Qure.ai lung cancer continuum platform reportedly automates lung nodule measurement on CT scans and facilitates multimodality reporting.
Offering multimodality potential in detecting, monitoring, and reporting of lung cancer, Qure.ai will introduce an artificial intelligence (AI)-enabled lung cancer continuum platform at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Key attributes of the lung cancer continuum platform include AI-enabled lung nodule measurement and tracking of volumetric growth of disease, according to Qure.ai, the developer of the platform. The company said the lung cancer continuum platform enables monitoring of drug efficacy, provides triage prioritization, and facilitates multimodality reporting.
Key attributes of the Qure. ai lung cancer continuum platform, slated to debut at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, include AI-enabled lung nodule detection, measurement and tracking of volumetric growth of lung disease, according to Qure.ai, the developer of the platform. (Image courtesy of Qure.ai.)
Qure.ai also emphasized the capability of the lung cancer continuum platform to improve early detection of lung cancer through detection of lung nodules missed on X-rays.
“Artificial intelligence for lung cancer powers early detection, not just as part of existing screening programs, but by finding small pulmonary nodules, often opportunistically, during general health-care imaging procedures,” noted Prashant Warier, the CEO and co-founder of Qure.ai. “This enables earlier identification and referral for imaging or treatment pathways. It also helps overcome the ongoing challenges of low lung cancer screening appointment uptake rates.”
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.